Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

• Published in: Microbiology spectrum Vol. 10; no. 5; p. e0292722
• Main Authors: Hernández-García, Marta, García-Castillo, María, Bou, Germán, Cercenado, Emilia, Delgado-Valverde, Mercedes, Oliver, Antonio, Pitart, Cristina, Rodríguez-Lozano, Jesús, Tormo, Nuria, Melo-Cristino, José, Pinto, Margarida F, Gonçalves, Elsa, Alves, Valquíria, Vieira, Ana Raquel, Ramalheira, Elmano, Sancho, Luísa, Diogo, José, Ferreira, Rui, Cruz, Hugo, Chaves, Catarina, Duarte, Joana, Pássaro, Leonor, Díaz-Regañón, Jazmín, Cantón, Rafael
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 26.10.2022
• Subjects: Anti-Bacterial Agents - pharmacology; beta-Lactamase Inhibitors - pharmacology; beta-Lactamases - genetics; carbapenemase-producing Enterobacterales; Clinical Microbiology; Drug Combinations; Escherichia coli - genetics; Humans; ICU patients; Imipenem - pharmacology; imipenem-relebactam susceptibility; Intensive Care Units; Klebsiella pneumoniae - genetics; Microbial Sensitivity Tests; Portugal; Research Article; Spain; Tazobactam - pharmacology; Portugal; Spain; carbapenemase-producing Enterobacterales; imipenem-relebactam susceptibility; Portugal; ICU patients; Spain
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.02927-22

Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the activity of imipenem-relebactam and comparators against clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (ICUs) (SUPERIOR, 2016-2017; STEP, 2017-2018). Overall, 747 isolates (378 Escherichia coli, 252 Klebsiella spp., 64 Enterobacter spp., and 53 other species) were prospectively collected from ICU patients with complicated intraabdominal (cIAI), complicated urinary tract (cUTI), and lower respiratory tract (LRTI) infections. MICs were determined (ISO-broth microdilution), and whole-genome sequencing (WGS) was performed in a subset of isolates displaying susceptible and resistant imipenem-relebactam MICs. Imipenem-relebactam (98.7% susceptible) showed similar activity to ceftazidime-avibactam (99.5% susceptible) and higher than ceftolozane-tazobactam (86.9% susceptible). Imipenem-relebactam was inactive against 1.3% (10/747) isolates, all of them due to carbapenemase production (9 K. pneumoniae and 1 E. cloacae). Imipenem-relebactam was active against 100% of extended-spectrum β-lactamase (ESBL)-E. coli and ESBL-Klebsiella spp. isolates and 80.4% of carbapenemase-Klebsiella spp. producers. Carbapenemase genes were confirmed by WGS in 41 Klebsiella spp.: OXA-48 (20/41), KPC-3 (14/41), OXA-181 (4/41), NDM-1 (1/41), OXA-48 + VIM-2 (1/41), and KPC-3 + VIM-2 (1/41). In Klebsiella spp. isolates, relebactam restored imipenem susceptibility in all KPC-3 producers, and resistant isolates (7/41) were mostly OXA-48 + CTX-M-15-K. pneumoniae high-risk clones (7/9). Intercountry differences were detected as follows: OXA-48 (17/21) was dominant in Spain, unlike KPC-3 (14/15) in Portugal. Imipenem-relebactam was 100% active against CTX-M-15-ST131-H30Rx-E. coli high-risk clone, predominant in both countries. Our results depict the potential role of imipenem-relebactam in ICU patients with cIAIs, cUTIs, and LRTIs due to wild-type ESBL- and carbapenemase-producing , particularly KPC producers. We comparatively evaluate the activity of a drug combination consisting of a carbapenem (imipenem) and a novel inhibitor of beta-lactamases (relebactam), a mechanism that destroys beta-lactam antibiotics. We assess the activity against a collection of clinical isolates recovered from difficult-to-treat infections in patients admitted to different intensive care units in Portugal and Spain. Imipenem-relebactam shows excellent activity in avoiding common resistance mechanisms in this setting, such as extended-spectrum beta-lactamases and carbapenemases widely distributed, including KPCs. We show few resistant isolates (<2%). Molecular characterization by whole-genome sequencing shows that most of the resistant isolates produced specific carbapenemase, such as OXA-48 or metalo-betalactamases. Our study updates the activity of imipenem-relebactam in light of current epidemiology in a hospital setting in which the use of this combination is needed due to the presence of infections due to multidrug-resistant isolates.